Matthew Henn's most recent trade in Seres Therapeutics Inc was a trade of 75,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on March 4, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2026 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2026 | 239 | 7,766 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2026 | 141 | 563 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2026 | 98 | 780 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Sale of securities on an exchange or to another person at price $ 8.47 per share. | 15 Feb 2026 | 89 | 7,677 (0%) | 0% | 8.5 | 754 | Common Stock |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2025 | 3,998 | 0 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2025 | 3,998 | 8,546 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Sale of securities on an exchange or to another person at price $ 17.30 per share. | 15 Nov 2025 | 1,257 | 7,527 (0%) | 0% | 17.3 | 21,746 | Common Stock |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2025 | 140 | 8,686 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2025 | 140 | 704 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2025 | 98 | 878 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2025 | 98 | 8,784 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2025 | 3,998 | 3,998 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 141 | 4,524 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 141 | 844 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 97 | 976 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2025 | 97 | 4,621 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Sale of securities on an exchange or to another person at price $ 16.64 per share. | 15 Aug 2025 | 73 | 4,548 (0%) | 0% | 16.6 | 1,215 | Common Stock |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 140 | 4,362 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 140 | 985 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 98 | 1,073 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 98 | 4,460 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Sale of securities on an exchange or to another person at price $ 7.29 per share. | 15 May 2025 | 77 | 4,383 (0%) | 0% | 7.3 | 561 | Common Stock |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 7,813 | 88,396 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 7,813 | 23,437 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Sale of securities on an exchange or to another person at price $ 0.81 per share. | 15 Feb 2025 | 3,953 | 84,443 (0%) | 0% | 0.8 | 3,204 | Common Stock |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 2,813 | 22,500 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 2,813 | 80,583 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 650,000 | 650,000 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2024 | 2,812 | 25,313 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2024 | 2,812 | 78,697 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Sale of securities on an exchange or to another person at price $ 0.54 per share. | 15 Nov 2024 | 927 | 77,770 (0%) | 0% | 0.5 | 501 | Common Stock |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Oct 2024 | 12,622 | 0 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Oct 2024 | 12,622 | 79,869 (0%) | 0% | 0 | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Sale of securities on an exchange or to another person at price $ 0.69 per share. | 27 Oct 2024 | 3,984 | 75,885 (0%) | 0% | 0.7 | 2,749 | Common Stock |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 2,813 | 28,125 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 2,813 | 68,170 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Sale of securities on an exchange or to another person at price $ 0.84 per share. | 15 Aug 2024 | 923 | 67,247 (0%) | 0% | 0.8 | 775 | Common Stock |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 2,812 | 66,248 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 2,812 | 30,938 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Sale of securities on an exchange or to another person at price $ 0.94 per share. | 15 May 2024 | 891 | 65,357 (0%) | 0% | 0.9 | 838 | Common Stock |
| Seres Therapeutics Inc | Henn Matthew | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 287,905 | 287,905 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | Henn Matthew | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 187,500 | 187,500 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 31,250 | 31,250 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 11,250 | 33,750 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 11,250 | 67,606 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Sale of securities on an exchange or to another person at price $ 1.08 per share. | 14 Feb 2024 | 4,170 | 63,436 (0%) | 0% | 1.1 | 4,504 | Common Stock |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2023 | 35,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 45,000 | 45,000 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Sep 2022 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Grant, award, or other acquisition of securities at price $ 3.15 per share. | 05 Jul 2022 | 47,619 | 47,619 (0%) | 0% | 3.2 | 150,000 | COMMON STOCK |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) |